In brief: Meditech, Psivida, Regenera, Mesoblast
Wednesday, 24 August, 2005
Cancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing.
Meanwhile, Robert Stewart has taken over as Meditech's chairman. Prof Richard Fox will remain as a non-executive director and will continue to advise the company on clinical development and medical issues.
Perth-based nanotech Psivida (ASX:PSD) has raised US$4.2 million before costs via the private placement of 650,000 on American Depository Receipts to predominantly US investors at US$6.50 each. Each ADR represents 10 ordinary shares.
Perth's Regenera (ASX:RGA) has received its first licensing payment of AUD$1.3 million from Alcon Manufacturing in accordance with an exclusive global license granted by Regenera to Alcon in April 2005. The license involves a steroid product that is used during ocular surgery. Adult stem cell company Mesoblast (ASX:MSB) has entered into an agreement with an unnamed medical device company which will provide carrier materials for use in Mesoblast's preclinical trials.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
